Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Science & Technology (61)
- Life Sciences & Biomedicine (59)
- Psychiatry (43)
- Schizophrenia (16)
- Neurosciences & Neurology (15)
-
- SCHIZOPHRENIA (12)
- METAANALYSIS (11)
- Neurosciences (10)
- Pharmacology & Pharmacy (9)
- DOUBLE-BLIND (8)
- Clinical Neurology (7)
- Psychosis (7)
- Social Sciences (7)
- BIPOLAR DISORDER (6)
- RANDOMIZED CONTROLLED-TRIAL (6)
- 1ST-EPISODE SCHIZOPHRENIA (5)
- GENOME-WIDE ASSOCIATION (5)
- General & Internal (5)
- Genetics & Heredity (5)
- LOCI (5)
- Psychology (5)
- 1ST EPISODE (4)
- 1ST-EPISODE PSYCHOSIS (4)
- DISORDER (4)
- EDUCATIONAL-ATTAINMENT (4)
- HUMAN BRAIN (4)
- MAINTENANCE TREATMENT (4)
- NEGATIVE SYMPTOMS (4)
- PREVALENCE (4)
- PSYCHOTIC DISORDERS (4)
Articles 241 - 270 of 278
Full-Text Articles in Psychiatry
The Content Of Attenuated Psychotic Symptoms In Those At Clinical High Risk For Psychosis, C. Marshall, E. Denny, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, J. Addington, +2 Additional Authors
The Content Of Attenuated Psychotic Symptoms In Those At Clinical High Risk For Psychosis, C. Marshall, E. Denny, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, J. Addington, +2 Additional Authors
Journal Articles
Recent research has started to focus on identifying individuals who are at clinical high risk of developing psychosis as a means to try and understand the predictors and mechanisms involved in the progress to a full psychotic episode. The aim of the current study was to provide an initial description and prevalence rates of specific content found within attenuated positive symptoms. The Content of Attenuated Positive Symptoms (CAPS) codebook was used by independent raters to determine the presence of content within a sample of written vignettes. Krippendorff's alpha was used to determine inter-rater reliability. Overall, the majority of items fell …
Bdnf Val66met Polymorphism And Antipsychotic-Induced Tardive Dyskinesia Occurrence And Severity: A Meta-Analysis, I. Miura, Jianping Zhang, M. Nitta, T. Lencz, John Kane, Anil Malhotra, H. Yabe, Christoph Correll
Bdnf Val66met Polymorphism And Antipsychotic-Induced Tardive Dyskinesia Occurrence And Severity: A Meta-Analysis, I. Miura, Jianping Zhang, M. Nitta, T. Lencz, John Kane, Anil Malhotra, H. Yabe, Christoph Correll
Journal Articles
Background: Tardive dyskinesia (TD) is a serious long-term consequence of antipsychotic treatment. Since brain-derived neurotrophic factor (BDNF) has potent neurotrophic activity, genetic alterations in the BDNF gene may affect antipsychotic-induced TD. Methods: Searching PubMed and Web of Science until 05/31/13, we conducted a systematic review and a meta-analysis of the effects of BDNF Val66Met polymorphism on antipsychotic-induced TD. Pooled odds ratio was calculated to assess the effects of BDNF Val66Met polymorphism on TD occurrence. Additionally, pooled standardized mean differences (Hedges'g) were calculated to assess the effects on Abnormal Involuntary Movement Scale (AIMS) total score. Results: Out of 699 potentially eligible …
Excess Of Homozygosity In The Major Histocompatibility Complex In Schizophrenia, S. Mukherjee, S. Guha, M. Ikeda, N. Iwata, Anil Malhotra, I. Pe'er, A. Darvasi, T. Lencz
Excess Of Homozygosity In The Major Histocompatibility Complex In Schizophrenia, S. Mukherjee, S. Guha, M. Ikeda, N. Iwata, Anil Malhotra, I. Pe'er, A. Darvasi, T. Lencz
Journal Articles
Genome-wide association studies (GWAS) in schizophrenia have focused on additive allelic effects to identify disease risk loci. In order to examine potential recessive effects, we applied a novel approach to identify regions of excess homozygosity in an ethnically homogenous cohort: 904 schizophrenia cases and 1640 controls drawn from the Ashkenazi Jewish (AJ) population. Genome-wide examination of runs of homozygosity identified an excess in cases localized to the major histocompatibility complex (MHC). To refine this signal, we used the recently developed GERMLINE algorithm to identify chromosomal segments shared identical-by-descent (IBD) and compared homozygosity at such segments in cases and controls. We …
Matrics Cognitive Consensus Battery (Mccb) Performance In Children, Adolescents, And Young Adults, G. C. Nitzburg, P. Derosse, K. E. Burdick, B. D. Peters, C. B. Gopin, Anil Malhotra
Matrics Cognitive Consensus Battery (Mccb) Performance In Children, Adolescents, And Young Adults, G. C. Nitzburg, P. Derosse, K. E. Burdick, B. D. Peters, C. B. Gopin, Anil Malhotra
Journal Articles
Background: Neurodevelopmental models of schizophrenia suggest that cognitive deficits may be observed during childhood and adolescence, long before the onset of psychotic symptoms. Elucidating the trajectory of normal cognitive development during childhood and adolescence may therefore provide a basis for identifying specific abnormalities related to the development of schizophrenia. The MATRICS Consensus Cognitive Battery (MCCB), which was designed for use in clinical trials targeting cognitive deficits most common in schizophrenia, may provide a mechanism to understand this trajectory. To date, however, there is no performance data for the MCCB in healthy children and adolescents. The present study sought to establish …
Age-Related Differences In White Matter Tract Microstructure Are Associated With Cognitive Performance From Childhood To Adulthood, B. D. Peters, T. Ikuta, P. Derosse, M. John, K. E. Burdick, P. Gruner, D. M. Prendergast, Philip Szeszko, Anil Malhotra
Age-Related Differences In White Matter Tract Microstructure Are Associated With Cognitive Performance From Childhood To Adulthood, B. D. Peters, T. Ikuta, P. Derosse, M. John, K. E. Burdick, P. Gruner, D. M. Prendergast, Philip Szeszko, Anil Malhotra
Journal Articles
Background: Age-related differences in white matter tract microstructure have been well established across the life span. In the present cross-sectional study, we examined whether these differences are associated with neurocognitive performance from childhood to late adulthood. Methods: Diffusion tensor imaging was performed in 296 healthy subjects aged 8 to 68 years (mean = 29.6, SD = 14.6). The corpus callosum, two projection tracts, and five association tracts were traced using probabilistic tractography. A neurocognitive test battery was used to assess speed of processing, attention, spatial working memory, verbal functioning, visual learning, and executive functioning. Linear mediation models were used to …
Brain White Matter Development Is Associated With A Human-Specific Haplotype Increasing The Synthesis Of Long Chain Fatty Acids, B. D. Peters, A. N. Voineskos, P. R. Szeszko, T. A. Lett, P. Derosse, S. Guha, K. H. Karlsgodt, M. John, T. Lencz, A. K. Malhotra, +4 Additional Authors
Brain White Matter Development Is Associated With A Human-Specific Haplotype Increasing The Synthesis Of Long Chain Fatty Acids, B. D. Peters, A. N. Voineskos, P. R. Szeszko, T. A. Lett, P. Derosse, S. Guha, K. H. Karlsgodt, M. John, T. Lencz, A. K. Malhotra, +4 Additional Authors
Journal Articles
The genetic and molecular pathways driving human brain white matter (WM) development are only beginning to be discovered. Long chain polyunsaturated fatty acids (LC-PUFAs) have been implicated in myelination in animal models and humans. The biosynthesis of LC-PUFAs is regulated by the fatty acid desaturase (FADS) genes, of which a human-specific haplotype is strongly associated with omega-3 and omega-6 LC-PUFA concentrations in blood. To investigate the relationship between LC-PUFA synthesis and human brain WM development, we examined whether this FADS haplotype is associated with age-related WM differences across the life span in healthy individuals 9-86 years of age (n = …
Delineation Of Hippocampal Subregions Using T1-Weighted Magnetic Resonance Images At 3 Tesla, K. Rhindress, T. Ikuta, R. Wellington, A. K. Malhotra, P. Szeszko
Delineation Of Hippocampal Subregions Using T1-Weighted Magnetic Resonance Images At 3 Tesla, K. Rhindress, T. Ikuta, R. Wellington, A. K. Malhotra, P. Szeszko
Journal Articles
Although several novel approaches for hippocampal subregion delineation have been developed, they need to be applied prospectively and may be limited by long scan times, the use of high field (>3T) imaging systems, and limited reliability metrics. Moreover, the majority of MR imaging data collected to date has employed a T1-weighted acquisition, creating a critical need for an approach that provides reliable hippocampal subregion segmentation using such a contrast. We present a highly reliable approach for the identification of six subregions comprising the hippocampal formation from MR images including the subiculum, dentate gyrus/cornu Ammonis 4 (DG/CA4), entorhinal cortex, fimbria, …
White Matter Changes Associated With Antipsychotic Treatment In First-Episode Psychosis, P. Szeszko, D. G. Robinson, T. Ikuta, B. D. Peters, J. Gallego, J. Kane, A. K. Malhotra
White Matter Changes Associated With Antipsychotic Treatment In First-Episode Psychosis, P. Szeszko, D. G. Robinson, T. Ikuta, B. D. Peters, J. Gallego, J. Kane, A. K. Malhotra
Journal Articles
Second-generation antipsychotics are utilized extensively in the treatment of psychotic disorders and other psychiatric conditions, but the effects of these medications on human brain white matter are not well understood. We thus investigated the effects of second-generation antipsychotics on white matter integrity using tract-based spatial statistics in patients experiencing a first episode of psychosis with little or no prior antipsychotic exposure, and how potential changes were associated with metabolic side effects. Thirty-five (26 men/9 women) patients experiencing a first episode of psychosis received diffusion tensor imaging (DTI) exams, clinical assessments, and provided fasting blood samples at the onset of antipsychotic …
Prevalence And Correlates Of Antipsychotic Polypharmacy In Children And Adolescents Receiving Antipsychotic Treatment*, N. Toteja, J. Gallego, E. Saito, T. Gerhard, A. Winterstein, M. Olfson, C. U. Correll
Prevalence And Correlates Of Antipsychotic Polypharmacy In Children And Adolescents Receiving Antipsychotic Treatment*, N. Toteja, J. Gallego, E. Saito, T. Gerhard, A. Winterstein, M. Olfson, C. U. Correll
Journal Articles
Antipsychotic polypharmacy (APP), which is common in adults with psychotic disorders, is of unproven efficacy and raises safety concerns. Although youth are increasingly prescribed antipsychotics, little is known about APP in this population. We performed a systematic PubMed search (last update 26 January 2013) of studies reporting the prevalence of APP in antipsychotic-treated youth. Summary statistics and statistical tests were calculated at the study level and not weighted by sample size. Fifteen studies (n=58041, range 68-23183) reported on APP in youth [mean age=13.4 +/- 1.7 yr, 67.1 +/- 10.2% male, 77.9 +/- 27.4% treated with second-generation antipsychotics (SGAs)]. Data collected …
Age-Associated Alterations In Corpus Callosum White Matter Integrity In Bipolar Disorder Assessed Using Probabilistic Tractography, N. Toteja, P. Guvenek-Cokol, T. Ikuta, V. Kafantaris, B. D. Peters, K. E. Burdick, M. John, A. K. Malhotra, P. Szeszko
Age-Associated Alterations In Corpus Callosum White Matter Integrity In Bipolar Disorder Assessed Using Probabilistic Tractography, N. Toteja, P. Guvenek-Cokol, T. Ikuta, V. Kafantaris, B. D. Peters, K. E. Burdick, M. John, A. K. Malhotra, P. Szeszko
Journal Articles
OBJECTIVES: Atypical age-associated changes in white matter integrity may play a role in the neurobiology of bipolar disorder, but no studies have examined the major white matter tracts using nonlinear statistical modeling across a wide age range in this disorder. The goal of this study was to identify possible deviations in the typical pattern of age-associated changes in white matter integrity in patients with bipolar disorder across the age range of 9-62 years. METHODS: Diffusion tensor imaging was performed in 57 (20 male and 37 female) patients with a diagnosis of bipolar disorder and 57 (20 male and 37 female) …
Genome-Wide Mapping Of Ibd Segments In An Ashkenazi Pd Cohort Identifies Associated Haplotypes, V. Vacic, L. J. Ozelius, L. N. Clark, A. Bar-Shira, M. Gana-Weisz, T. Gurevich, A. Gusev, S. Guha, T. Lencz, A. Orr-Urtreger, +10 Additional Authors
Genome-Wide Mapping Of Ibd Segments In An Ashkenazi Pd Cohort Identifies Associated Haplotypes, V. Vacic, L. J. Ozelius, L. N. Clark, A. Bar-Shira, M. Gana-Weisz, T. Gurevich, A. Gusev, S. Guha, T. Lencz, A. Orr-Urtreger, +10 Additional Authors
Journal Articles
The recent series of large genome-wide association studies in European and Japanese cohorts established that Parkinson disease (PD) has a substantial genetic component. To further investigate the genetic landscape of PD, we performed a genome-wide scan in the largest to date Ashkenazi Jewish cohort of 1130 Parkinson patients and 2611 pooled controls. Motivated by the reduced disease allele heterogeneity and a high degree of identical-by-descent (IBD) haplotype sharing in this founder population, we conducted a haplotype association study based on mapping of shared IBD segments. We observed significant haplotype association signals at three previously implicated Parkinson loci: LRRK2 (OR = …
Hospitalization Rates In Patients Switched From Oral Anti-Psychotics To Aripiprazole Once-Monthly: Final Efficacy Analysis, John Kane, C. Zhao, B. R. Johnson, R. A. Baker, A. Eramo, R. D. Mcquade, A. R. Duca, R. Sanchez, T. Peters-Strickland
Hospitalization Rates In Patients Switched From Oral Anti-Psychotics To Aripiprazole Once-Monthly: Final Efficacy Analysis, John Kane, C. Zhao, B. R. Johnson, R. A. Baker, A. Eramo, R. D. Mcquade, A. R. Duca, R. Sanchez, T. Peters-Strickland
Journal Articles
Abstract Objective: To compare hospitalization rates in patients with schizophrenia treated prospectively with aripiprazole once-monthly 400 mg (AOM 400; an extended-release injectable suspension) vs the same patients' retrospective rates with their prior oral anti-psychotic therapy. Research design and methods: Multi-center, open-label, mirror-image, naturalistic study in a community setting in North America. Patients who required a change in treatment and/or would benefit from long-acting injectable anti-psychotic therapy were treated prospectively for 6 months with AOM 400. Retrospective data on hospitalization rates were obtained. Clinical trial registration: ClinicalTrials.gov: NCT01432444. Main outcome measures: The proportion of patients with >/=1 psychiatric inpatient hospitalization with …
Optimal Treatment Of Alzheimer's Disease Psychosis: Challenges And Solutions, Jeremy Koppel, Blaine Greenwald
Optimal Treatment Of Alzheimer's Disease Psychosis: Challenges And Solutions, Jeremy Koppel, Blaine Greenwald
Journal Articles
Psychotic symptoms emerging in the context of neurodegeneration as a consequence of Alzheimer's disease was recognized and documented by Alois Alzheimer himself in his description of the first reported case of the disease. Over a quarter of a century ago, in the context of attempting to develop prognostic markers of disease progression, psychosis was identified as an independent predictor of a more-rapid cognitive decline. This finding has been subsequently well replicated, rendering psychotic symptoms an important area of exploration in clinical history taking - above and beyond treatment necessity - as their presence has prognostic significance. Further, there is now …
The Relationship Of Neurocognition And Negative Symptoms To Social And Role Functioning Over Time In Individuals At Clinical High Risk In The First Phase Of The North American Prodrome Longitudinal Study, E. C. Meyer, Ricardo Carrion, Barbara Cornblatt, J. Addington, K. S. Cadenhead, T. D. Cannon, T. H. Mcglashan, D. O. Perkins, M. T. Tsuang, L. J. Seidman, +3 Additional Authors
The Relationship Of Neurocognition And Negative Symptoms To Social And Role Functioning Over Time In Individuals At Clinical High Risk In The First Phase Of The North American Prodrome Longitudinal Study, E. C. Meyer, Ricardo Carrion, Barbara Cornblatt, J. Addington, K. S. Cadenhead, T. D. Cannon, T. H. Mcglashan, D. O. Perkins, M. T. Tsuang, L. J. Seidman, +3 Additional Authors
Journal Articles
OBJECTIVES: Impaired social, role, and neurocognitive functioning are preillness characteristics of people who later develop psychosis. In people with schizophrenia, neurocognition and negative symptoms are associated with functional impairment. We examined the relative contributions of neurocognition and symptoms to social and role functioning over time in clinically high-risk (CHR) individuals and determined if negative symptoms mediated the influence of cognition on functioning. METHODS: Social, role, and neurocognitive functioning and positive, negative, and disorganized symptoms were assessed in 167 individuals at CHR for psychosis in the North American Prodrome Longitudinal Study Phase 1 (NAPLS-1), of whom 96 were reassessed at 12 …
Comparative Effectiveness Of Risperidone Long-Acting Injectable Vs First-Generation Antipsychotic Long-Acting Injectables In Schizophrenia: Results From A Nationwide, Retrospective Inception Cohort Study, J. Nielsen, S. O. Jensen, R. B. Friis, J. B. Valentin, Christoph Correll
Comparative Effectiveness Of Risperidone Long-Acting Injectable Vs First-Generation Antipsychotic Long-Acting Injectables In Schizophrenia: Results From A Nationwide, Retrospective Inception Cohort Study, J. Nielsen, S. O. Jensen, R. B. Friis, J. B. Valentin, Christoph Correll
Journal Articles
Objective: To compare in a generalizable sample/setting objective outcomes in patients receiving first-generation antipsychotic long-acting injectables (FGA-LAIs) or risperidone-LAI (RIS-LAI). Methods: Nationwide, retrospective inception cohort study of adults with International Classification of Diseases-10 schizophrenia using Danish registers from 1995 to 2009 comparing outcomes between clinician's/patient's choice treatment with FGA-LAIs or RIS-LAI. Primary outcome was time to psychiatric hospitalization using Cox-regression adjusting for relevant covariates. Secondary outcomes included time to all-cause discontinuation and psychiatric hospitalization in patients without LAI possession gap >28 days, and number of bed-days after psychiatric hospitalization. Results: Among 4532 patients followed for 2700 patient-years, 2078 received RIS-LAI …
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Journal Articles
Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments …
Towards A Psychosis Risk Blood Diagnostic For Persons Experiencing High-Risk Symptoms: Preliminary Results From The Napls Project, D. O. Perkins, C. D. Jeffries, J. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, D. H. Mathalon, S. W. Woods, R. Heinssen, +4 Additional Authors
Towards A Psychosis Risk Blood Diagnostic For Persons Experiencing High-Risk Symptoms: Preliminary Results From The Napls Project, D. O. Perkins, C. D. Jeffries, J. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, D. H. Mathalon, S. W. Woods, R. Heinssen, +4 Additional Authors
Journal Articles
INTRODUCTION: A barrier to preventative treatments for psychosis is the absence of accurate identification of persons at highest risk. A blood test that could substantially increase diagnostic accuracy would enhance development of psychosis prevention interventions. METHODS: The North American Prodrome Longitudinal Study project is a multisite endeavor that aims to better understand predictors and mechanisms for the development of psychosis. In this study, we measured expression of plasma analytes reflecting inflammation, oxidative stress, hormones, and metabolism. A "greedy algorithm" selected analytes that best distinguished persons with clinical high-risk symptoms who developed psychosis (CHR-P; n = 32) from unaffected comparison (UC) …
Child And Adolescent Psychiatrists' Attitudes And Practices Prescribing Second Generation Antipsychotics, A. M. Rodday, S. K. Parsons, C. U. Correll, A. S. Robb, B. T. Zima, T. S. Saunders, L. K. Leslie
Child And Adolescent Psychiatrists' Attitudes And Practices Prescribing Second Generation Antipsychotics, A. M. Rodday, S. K. Parsons, C. U. Correll, A. S. Robb, B. T. Zima, T. S. Saunders, L. K. Leslie
Journal Articles
Objective: The purpose of this study was to examine psychiatrists' attitudes and practices in prescribing second-generation antipsychotics (SGA) to children and adolescents (referred to here as "children") and identify factors associated with off-label SGA use. Methods: A survey was mailed to a national, randomly selected sample of 1600 child and adolescent psychiatrists identified by the American Medical Association. Multivariable logistic regression was used to identify factors, including psychiatrists' characteristics, practice characteristics, and psychiatrists' attitudes, that are associated with off-label SGA use (i.e., SGAs used in children with attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder, or nonbipolar mood disorders). Results: …
Perceived Discrimination In Those At Clinical High Risk For Psychosis, M. M. Saleem, J. Stowkowy, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, S. W. Woods, +2 Additional Authors
Perceived Discrimination In Those At Clinical High Risk For Psychosis, M. M. Saleem, J. Stowkowy, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, S. W. Woods, +2 Additional Authors
Journal Articles
Aim: There is evidence to suggest that perceived discrimination may be associated with psychosis. Less is known about its potential impact on those at clinical high risk (CHR) for psychosis. The aim of this study was to determine the prevalence of perceived discrimination in a CHR sample and its possible relationship to attenuated positive symptoms and negative self-beliefs. Methods: Participants were 360 CHR individuals and 180 healthy controls. Assessments included a self-report measure of perceived discrimination, the Scale of Prodromal Symptoms and the Brief Core Schema Scale. Results: CHR participants reported significantly more perceived discrimination. Perceived discrimination was significantly associated …
Antidepressants For Cognitive Impairment In Schizophrenia - A Systematic Review And Meta-Analysis, J. A. Vernon, E. Grudnikoff, A. J. Seidman, T. W. Frazier, M. S. Vemulapalli, P. Pareek, T. Goldberg, J. Kane, C. U. Correll
Antidepressants For Cognitive Impairment In Schizophrenia - A Systematic Review And Meta-Analysis, J. A. Vernon, E. Grudnikoff, A. J. Seidman, T. W. Frazier, M. S. Vemulapalli, P. Pareek, T. Goldberg, J. Kane, C. U. Correll
Journal Articles
Background: Cognitive impairment in schizophrenia is disabling, but current treatment options remain limited. Objective: To meta-analyze the efficacy and safety of adjunctive antidepressants for cognitive impairment in schizophrenia. Data sources and study selection: PubMed, MEDLINE, PsycINFO, and Cochrane Library databases were searched until 12/2013 for randomized controlled trials comparing antidepressant augmentation of antipsychotics with placebo regarding effects on cognitive functioning in schizophrenia. Data extraction: Two authors independently extracted data. Standardized mean differences (SMDs) were calculated for continuous outcomes and risk ratios for categorical outcomes. SMDs of individual cognitive tests were pooled on a study level within domains (primary outcome) and …
Current Status Specifiers For Patients At Clinical High Risk For Psychosis, S. W. Woods, B. C. Walsh, J. Addington, K. S. Cadenhead, T. D. Cannon, B. A. Cornblatt, R. Heinssen, D. O. Perkins, L. J. Seidman, T. H. Mcglashan, + 3 Additional Authors
Current Status Specifiers For Patients At Clinical High Risk For Psychosis, S. W. Woods, B. C. Walsh, J. Addington, K. S. Cadenhead, T. D. Cannon, B. A. Cornblatt, R. Heinssen, D. O. Perkins, L. J. Seidman, T. H. Mcglashan, + 3 Additional Authors
Journal Articles
Background: Longitudinal studies of the clinical high risk (CHR) syndrome for psychosis have emphasized the conversion vs non-conversion distinction and thus far have not focused intensively on classification among non-converters. The present study proposes a system for classifying CHR outcomes over time when using the Structured Interview for Psychosis-risk Syndromes and evaluates its validity. Method: The system for classifying CHR outcomes is referred to as "current status specifiers," with "current" meaning over the month prior to the present evaluation and "specifiers" indicating a set of labels and descriptions of the statuses. Specifiers for four current statuses are described: progression, persistence, …
The 12th Annual Pharmacogenetics In Psychiatry Meeting Report, J. Zhang, K. J. Aitchison, A. K. Malhotra
The 12th Annual Pharmacogenetics In Psychiatry Meeting Report, J. Zhang, K. J. Aitchison, A. K. Malhotra
Journal Articles
The 12th Annual Pharmacogenetics in Psychiatry meeting was held in Hollywood, Florida, from 31 May to 1 June 2013, in conjunction with the NCDEU meeting. It included a series of oral presentations as well as a poster session. This report summarizes the presentations at the conference. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Prospective Memory Performance In Non-Psychotic First-Degree Relatives Of Patients With Schizophrenia: A Controlled Study, F. C. Zhou, W. M. Hou, C. Y. Wang, G. S. Ungvari, H. F. K. Chiu, C. U. Correll, D. H. K. Shum, D. Man, D. T. Liu, Y. T. Xiang
Prospective Memory Performance In Non-Psychotic First-Degree Relatives Of Patients With Schizophrenia: A Controlled Study, F. C. Zhou, W. M. Hou, C. Y. Wang, G. S. Ungvari, H. F. K. Chiu, C. U. Correll, D. H. K. Shum, D. Man, D. T. Liu, Y. T. Xiang
Journal Articles
Objective: We aimed at investigating prospective memory and its socio-demographic and neurocognitive correlates in nonpsychotic, first-degree relatives (FDRs) of patients with schizophrenia compared to patients with first episode schizophrenia (FES), and healthy controls (HCs). Methods: Forty-seven FES patients, 50 non-psychotic FDRs (23 offspring and 27 siblings) of patients with chronic schizophrenia (unrelated to the FES group) and 51 HCs were studied. The Chinese version of the Cambridge Prospective Memory Test (C-CAMPROMPT) was used to measure time-based prospective memory (TBPM) and event-based prospective memory (EBPM) performance. Other cognitive functions (involving respective memory and executive functions) were evaluated with standardized tests. Results: …
Substance Use In Clinical High Risk For Psychosis: A Review Of The Literature, J. Addington, N. Case, M. M. Saleem, A. M. Auther, B. A. Cornblatt, K. S. Cadenhead
Substance Use In Clinical High Risk For Psychosis: A Review Of The Literature, J. Addington, N. Case, M. M. Saleem, A. M. Auther, B. A. Cornblatt, K. S. Cadenhead
Journal Articles
AimIn the literature, there is evidence suggesting an association between substance use and psychosis. However, little is known about substance use in those who may be in the pre-psychotic phase, that is, those who are putatively prodromal are considered to be at clinical high risk (CHR) of developing psychosis. MethodsWe conducted a review of publications measuring patterns and rates of substance use in CHR for psychosis individuals and the effects on the transition to psychosis. ResultsOf 5527 potentially relevant research papers, 10 met inclusion criteria of CHR subjects and specifically mentioned substance use in the sample. The results of these …
The Subjective Experience Of Youths At Clinically High Risk Of Psychosis: A Qualitative Study, S. Ben-David, M. L. Birnbaum, M. E. Eilenberg, J. E. Devylder, K. E. Gill, J. Schienle, N. Azimov, E. P. Lukens, L. Davidson, C. M. Corcoran
The Subjective Experience Of Youths At Clinically High Risk Of Psychosis: A Qualitative Study, S. Ben-David, M. L. Birnbaum, M. E. Eilenberg, J. E. Devylder, K. E. Gill, J. Schienle, N. Azimov, E. P. Lukens, L. Davidson, C. M. Corcoran
Journal Articles
Objective: Understanding the experience of individuals across stages of schizophrenia is important for development of services to promote recovery. As yet, little is known about the experience of individuals who exhibit prodromal symptoms of schizophrenia. Methods: Audiotaped interviews were conducted with 27 participants of diverse racial-ethnic backgrounds who were at clinically high risk of psychosis (15 males and 12 females; mean age 21). Phenomenological qualitative research techniques of coding, consensus, and comparison were used. Results: Emergent themes differed by gender. Themes for males were feeling abnormal or "broken," focus on going " crazy," fantasy and escapism, and alienation and despair, …
Effectiveness Of Lurasidone In Schizophrenia Or Schizoaffective Patients Switched From Other Antipsychotics: A 6-Month, Open-Label, Extension Study, L. Citrome, P. J. Weiden, J. P. Mcevoy, C. U. Correll, J. Cucchiaro, J. Hsu, A. Loebel
Effectiveness Of Lurasidone In Schizophrenia Or Schizoaffective Patients Switched From Other Antipsychotics: A 6-Month, Open-Label, Extension Study, L. Citrome, P. J. Weiden, J. P. Mcevoy, C. U. Correll, J. Cucchiaro, J. Hsu, A. Loebel
Journal Articles
Objective. To evaluate the long-term safety and tolerability of lurasidone in schizophrenia and schizoaffective disorder patients switched to lurasidone. Method. Patients in this multicenter, 6-month open-label, flexible-dose, extension study had completed a core 6-week randomized trial in which clinically stable, but symptomatic, outpatients with schizophrenia or schizoaffective disorder were switched to lurasidone. Patients started the extension study on treatment with the same dose of lurasidone taken at study endpoint of the 6-week core study; following this, lurasidone was flexibly dosed (40-120 mg/day), if clinically indicated, starting on Day 7 of the extension study. The primary safety endpoints were the proportion …
Neural Activation During Response Inhibition In Adult Attention-Deficit/Hyperactivity Disorder: Preliminary Findings On The Effects Of Medication And Symptom Severity, E. Congdon, L. L. Altshuler, J. A. Mumford, K. H. Karlsgodt, F. W. Sabb, J. Ventura, E. D. London, T. D. Cannon, R. M. Bilder, R. A. Poldrack, +1 Additional Author
Neural Activation During Response Inhibition In Adult Attention-Deficit/Hyperactivity Disorder: Preliminary Findings On The Effects Of Medication And Symptom Severity, E. Congdon, L. L. Altshuler, J. A. Mumford, K. H. Karlsgodt, F. W. Sabb, J. Ventura, E. D. London, T. D. Cannon, R. M. Bilder, R. A. Poldrack, +1 Additional Author
Journal Articles
Studies of adults with attention-deficit/hyperactivity disorder (ADHD) have suggested that they have deficient response inhibition, but findings concerning the neural correlates of inhibition in this patient population are inconsistent. We used the Stop Signal task and functional magnetic resonance imaging (fMRI) to compare neural activation associated with response inhibition between adults with ADHD (N=35) and healthy comparison subjects (N=62), and in follow-up tests to examine the effect of current medication use and symptom severity. There were no differences in Stop Signal task performance or neural activation between ADHD and control participants. Among the ADHD participants, however, significant differences were associated …
Effects Of Aripiprazole Once-Monthly On Domains Of Personal And Social Performance: Results From 2 Multicenter, Randomized, Double-Blind Studies, W. W. Fleischhacker, R. A. Baker, A. Eramo, R. Sanchez, L. F. Tsai, T. Peters-Strickland, P. P. Perry, R. D. Mcquade, B. R. Johnson, W. H. Carson, J. M. Kane
Effects Of Aripiprazole Once-Monthly On Domains Of Personal And Social Performance: Results From 2 Multicenter, Randomized, Double-Blind Studies, W. W. Fleischhacker, R. A. Baker, A. Eramo, R. Sanchez, L. F. Tsai, T. Peters-Strickland, P. P. Perry, R. D. Mcquade, B. R. Johnson, W. H. Carson, J. M. Kane
Journal Articles
Objective: To assess the effects of maintenance therapy with aripiprazole once-monthly 400 mg on personal and social functioning. Methods: Data were analyzed from 2 randomized, double-blind trials of patients with schizophrenia requiring chronic antipsychotic treatment. One study was a 52-week trial of aripiprazole once-monthly 400 mg versus placebo; the other was a 38-week trial of aripiprazole once-monthly 400 mg, oral aripiprazole (10-30 mg daily), and aripiprazole once-monthly 50 mg (subtherapeutic dose to test assay sensitivity). Functioning was assessed using the Personal and Social Performance (PSP) scale, comprising 4 domain subscales. Results: In the 52-week study, 403 patients stabilized on aripiprazole …
Predicting Risky Choices From Brain Activity Patterns, S. M. Helfinstein, T. Schonberg, E. Congdon, K. H. Karlsgodt, J. A. Mumford, F. W. Sabb, T. D. Cannon, E. D. London, R. M. Bilder, R. A. Poldrack
Predicting Risky Choices From Brain Activity Patterns, S. M. Helfinstein, T. Schonberg, E. Congdon, K. H. Karlsgodt, J. A. Mumford, F. W. Sabb, T. D. Cannon, E. D. London, R. M. Bilder, R. A. Poldrack
Journal Articles
Previous research has implicated a large network of brain regions in the processing of risk during decision making. However, it has not yet been determined if activity in these regions is predictive of choices on future risky decisions. Here, we examined functional MRI data from a large sample of healthy subjects performing a naturalistic risk-taking task and used a classification analysis approach to predict whether individuals would choose risky or safe options on upcoming trials. We were able to predict choice category successfully in 71.8% of cases. Searchlight analysis revealed a network of brain regions where activity patterns were reliably …
Latent Factor Modeling Of Four Schizotypy Dimensions With Theory Of Mind And Empathy, J. S. Bedwell, M. T. Compton, F. G. Jentsch, A. E. Deptula, S. M. Goulding, E. B. Tone
Latent Factor Modeling Of Four Schizotypy Dimensions With Theory Of Mind And Empathy, J. S. Bedwell, M. T. Compton, F. G. Jentsch, A. E. Deptula, S. M. Goulding, E. B. Tone
Journal Articles
Preliminary evidence suggests that theory of mind and empathy relate differentially to factors of schizotypy. The current study assessed 686 undergraduate students and used structural equation modeling to examine links between a four-factor model of schizotypy with performance on measures of theory of mind (Reading the Mind in the Eyes Test [MIE]) and empathy (Interpersonal Reactivity Index [IRI]). Schizotypy was assessed using three self-report measures which were simultaneously entered into the model. Results revealed that the Negative factor of schizotypy showed a negative relationship with the Empathy factor, which was primarily driven by the Empathic Concern subscale of the IRI …